Precision Oncology Platforms & AI-Enabled Decision Support
Sequencing data are useful only if clinicians can act on them. Our RADAR precision medicine platform turns WGS, WES and RNA-seq into an annotated PDF that supports clinical decision-making. A forthcoming AI layer, PROMETHEUS, will merge genomic results, patient records, and up-to-date literature into a dashboard that ranks therapy options and lets physicians explore each case in plain language.
RADAR platform for precision oncology
We have developed a Nextflow-based platform, RADAR, which processes and analyzes WES/WGS and RNA-seq to generate treatment reports MM patients. In an early pilot trial, 26 patients received matched therapy and 76 % showed clinical benefit. The study demonstrated that adding RNA-based drug repurposing doubles the actionable options compared with DNA alone. [more]
Sequencing-guided salvage therapy in advanced-stage patients
Whole-exome sequencing of a post-BCMA CAR-T relapse uncovered a dominant BRAF V600E clone. In vitro testing guided triple MAPK blockade that achieved VGPR for 110 days, bridging the patient to further trials. This work illustrates RADAR-enabled precision rescue in the CAR-T failure setting. [more]
Ongoing projects
PROMETHEUS
Current tools list variants without ranking them or linking them to the patient’s clinical story. Clinicians must therefore sift through lengthy reports, cross-check the latest studies and guidelines by hand, and make decisions without automated support. PROMETHEUS tackles this gap by coupling our RADAR sequencing pipeline to a large-language-model (LLM) engine that continuously scans the literature, clinical-trial registries, and practice guidelines. The system re-scores variants as new findings emerge, ranks treatment options with supporting citations, and lets physicians query a patient’s data in plain language.